Domain Therapeutics

Page d'Accueil
France
Strasbourg
Domain Therapeutics

Informations de contact, plan et itinéraire, formulaire de contact, heures d'ouverture, services, évaluations, photos, vidéos et annonces de Domain Therapeutics, Compagnie pharmaceutique, BioParc – 850 Bld Sébastien Brant, Strasbourg.

Domain Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative treatments for immuno-oncology.
[EN]

Domain Therapeutics is a biopharmaceutical company dedicated to the discovery and development of new drug candidates targeting G Protein-Coupled Receptors(GPCRs), one of the most important classes of drug targets. With teams at work in France and Canada, Domain operates multiple technologies aimed at validating targets and discovering first-in-class therapies (small molecules or antibodies). It creates a pipeline of high-value programs in immuno-oncology, neurology and rare diseases which are developed as proprietary programs up to early clinical phases or in collaboration with pharma partners.

[FR]

Domain Therapeutics est une société biopharmaceutique dédiée à la découverte et au développement de nouveaux candidats médicaments ciblant les récepteurs couplés aux protéines G (GPCR), l'une des classes de cibles médicamenteuses les plus importantes. Avec des équipes basées en France et au Canada, Domain exploite de multiples technologies visant à valider des cibles et à découvrir des thérapies de premier ordre (petites molécules ou anticorps), crée un pipeline de programmes de forte valeur ajoutée en immuno-oncologie, neurologie et maladies rares, développés seuls jusqu'aux premières phases cliniques ou en collaboration avec des partenaires pharmaceutiques.

20/09/2024

At Domain Therapeutics, sustainability is in our DNA 🌱 As a company, we’re committed to innovative therapies and a greener planet.

With today, we're excited to share our recent eco-friendly initiatives:

🔬 Lab Clean-Up: We've given a second life to lab benches and equipment by donating them to local faculties Institut de Physique et de Chimie des Matériaux de Strasbourg - IPCMS ECPM Strasbourg : Ecole européenne de chimie, polymères et matériaux

♻️ Recycle & Repurpose: From donating furniture to selling equipment with anti-waste experts Labsquare, we're ensuring nothing goes to waste.

🔄 Sustainable Partnerships: Teaming up with R’SEEDS for waste sorting and Rosachem for recycling unused equipment, we're making a collaborative effort.

💻 IT Sustainability: By extending the life of our PCs beyond 5 years through repairs, we are reducing e-waste.

These actions are part of our vision to foster a culture of sustainability and drive . Every small act counts!

🙏 Special thanks to our partners for helping us minimize waste. Together, we can create a cleaner, healthier, waste-free future! 🌳
Let's make a difference together!

World Cleanup Day

18/09/2024

Thank you, ESMO - European Society for Medical Oncology 2024! We had an amazing time connecting with the community and sharing our latest breakthroughs in GPCR-targeting therapies. Meeting so many passionate experts was truly inspiring! 💬✨

At Domain Therapeutics, we’re developing innovative treatments that help the immune system recognize and attack cancer cells more efficiently. Our lead candidate, DT-9081, currently in a clinical trial, is designed to target a specific receptor EP4 to boost the efficacy and safety of existing therapies. Early results are promising, giving us hope for better outcomes in .

We’re also making strides with our CCR8-targeting antibody, DT-7012, which aims to remove the immune cells that protect tumors, and DT-9045, which blocks the PAR2 receptor, opening new avenues for treating tumors with high unmet needs. These therapies are part of our precision-driven approach, making sure treatments address patient-specific needs, preventing tumor growth and metastasis.

The insights from ESMO reaffirm the importance of our approach. We’re committed to pushing the boundaries of and improving patient outcomes. 💪

13/09/2024

Discover how targeting the EP4 receptor can revolutionize and improve patient outcomes. EP4 antagonists are a game-changer in , offering new hope in .

At Domain, we’re leading the change with our best-in-class EP4 receptor (EP4R) antagonist program: DT-9081. This clinical candidate not only reduces immunosuppressive cells but also boosts the activity of immune cells, promising a safer and more effective treatment.

Let’s work together to bring new hope to patients worldwide! 🌍💡

11/09/2024

🌧️Rain or shine, Apéropool was a blast!
The unexpected downpours and a thunder-triggered fire alarm didn’t impact the spirit at ‌Biovalley France’s event. Last week, our team had a pleasure of diving into the Région Grand EstEst health ecosystem, connecting with passionate health innovators and local entrepreneurs at Strasbourg’s historic municipal baths.

As part of this vibrant ecosystem, Domain Therapeutics is committed to driving innovations. By targeting GPCR-mediated immunosuppression, we aim to restore immune system functionality and bring hope to patients facing therapeutic failure. Our proprietary R&D programs are progressing promising drug candidates into the clinic.

Huge thanks to Biovalley France for an amazing event!
Together we can push the boundaries of ! 🚀

30/08/2024

🚀We’re thrilled to announce that our company has been nominated for the prestigious USA in the “Best Startup” category!🏆 This honor reflects our dedication to and excellence in developing groundbreaking treatments.

At Domain, we're pioneering new frontiers in by integrating G Protein-Coupled Receptors (GPCRs) and the immune system. Our cutting-edge research aims to redefine possibilities and offer new hope to patients worldwide.

🗓️Save the Date: Join us at the Prix Galien USA Forum on November 7th. Winners will be announced!

Thank you to Galien Foundation and Business France for this recognition. And a huge shoutout to visionary international venture capital firms, including 3B Future Health Fund I & II, Seventure Partners, Schroders, Omnes, Turenne Groupe, Theodorous Investment Funds, Panacea Venture, Viva BioInnovator, CTI Life Sciences Fund and AdMare BioInnovations for believing in our mission.

Together, we’re revolutionizing precision-enabled immunotherapies, making them accessible to patients worldwide! 🌍✨

30/07/2024

Sarcoma Awareness Month is a powerful reminder of this rare tumor that often goes unnoticed until it’s too late. Patients deserve breakthroughs beyond conventional treatments!

At Domain, we're a part of the groundbreaking RHU Condor program for Soft Tissue Sarcoma (STS). Our multidisciplinary team, led by Prof. Antoine Italiano, a valuable member of Domain's Scientific Advisory Board, is pioneering a unique strategy combining and .

🔬How are we making a difference?
-Leveraging 20+ years of GPCR expertise
-Advanced knowledge of the tumor microenvironment
-Precision tools and biomarkers

Our lead clinical candidate in this project, DT-9081, an EP4R antagonist, aims to improve immune responses to sarcoma and address resistance mechanisms to current therapies.

📢 Learn more about sarcoma in the illustration below. Share this post to amplify awareness and support the fight against this challenging disease.
Together, we can make a difference. 💪

24/07/2024

As we approach the 2-year anniversary of our proprietary choir, Domain Therap N Sing, we’re excited to share a heartwarming summer story that recently unfolded. Our talented choir members from various departments, united by their love for music, came together once again to spread joy beyond Domain’s corporate walls.

Twice a year, Domain Therap N Sing performs at the retirement home Ehpad Abrapa Illkirch, thanks to the remarkable volunteer association Les Blouses Roses Strasbourg. This summer’s concert was a beautiful blend of voices, stirring emotions and creating unforgettable moments.

Why is this important? Music has a profound impact on well-being. It eases stress, lifts spirits and bridges generational gaps. Our concerts create lasting bonds and bring joy to both young and elderly.

Special thanks to:
-Angélique Quille, President of Les Blouses Roses Strasbourg
-Manuella Rovira, our dedicated singing teacher
-Our management for providing us with this wonderful opportunity!

Music stimulates creativity and focus, just like the precision science at the heart of Domain. Together, we harmonize science and art!
Let’s keep the rhythm alive and make a difference, one note at a time.

11/07/2024

🚲💚 We did it, TEAM! We’ve pedaled our way to the 8th spot out of 246 participants in our category in the 15th anniversary edition of the “Bike to Work” challenge (Auboulotavelo)! That’s a big leap from last year, getting closer to the top finalists! 🏆

We’re thrilled to share our results with you:
-we’ve cycled an impressive 6,691.83 kilometers - that’s like biking from Paris to Chicago! 🌎
-we’ve cut down our carbon footprint by about 1,500 kg of CO2 - equivalent to the CO2 absorbed by 75 trees in a year or powering 29387 online searches. 🌳

Many of us have embraced the joy of cycling to work or use of public transport all year around. This challenge has not only brought out our team spirit but also highlighted the positive impact of our daily commutes on the environment and our health.

At Domain Therapeutics, we’re not just pioneering GPCR-targeting therapies. We’re making everyday choices that reflect our commitment to and making a difference in our communities. 🌏

We’re proud of our policy that encourages eco-friendly commuting. Cycling to work isn't just practical and economical - it’s a fun, energizing and eco-friendly choice that can make a real difference.

A huge shout-out to everyone who participated and supported this initiative! 🙌 Check out the video capturing our enthusiasm, cycling and summertime vibes!

Let's keep this momentum going, both on and off the bike. Here’s to enjoying the outdoors and working towards a greener, healthier, and more sustainable future together!

We’d love to hear your stories too! Share your cycling experiences, tips and photos with us using the hashtags . Let’s inspire each other to keep pedaling! 🚲💚

Strasbourg.eu

13/06/2024

🚴🚴‍♀️ This June, team Domain is once again rising to the challenge of Bike to work (Au boulot à vélo)! Every kilometer cycled, whether commuting, attending meetings, business trips, or even working from home, contributes to our collective goal. It’s simple: we’re swapping four wheels for two! 🚴🚴‍♀️

What if your daily commute could boost your health, team spirit and save the planet? 😉
👉 . Cycling to work keeps us fit, energized and ready to tackle the day!
👉 . By choosing bikes over cars, we are reducing pollution and easing urban traffic!
👉 . it isn’t just about the distance, it’s about the collective effort!
👉 . Cycling to work is one of the many ways we’re committed to protecting the environment, a commitment that is deeply embedded into our company’s DNA.💚

Last year, we pedaled nearly 10,000 kilometers, securing the 9th spot out of 243 teams. That’s 2.53 tons of CO2 emissions avoided, equivalent to a trip from Paris to La Réunion!
This year, we’re aiming to go even further. 💪

🙏 A big thank you to everyone representing our in this sporting and collaborative challenge. And guess what? Many of us at Domain don’t limit ourselves to just one month, we enjoy cycling year-round!

So grab your helmets, oil those chains, and together, let’s pedal toward a healthier and greener future! 🌍🌱

30/05/2024

Did you know that some skin conditions could be more than what they seem?

This May, as we observe , let’s shed light on rare cancers that affect the skin, such as cutaneous T-cell lymphoma (CTCL), which may be mistaken for noncancerous conditions, such as eczema and psoriasis, leading to delayed diagnosis and treatment.

CTCL affects about one in 100,000 adults worldwide annually, nearly tripling in last 30 years. With a median survival rate of less than 5 years for advanced stages and no established standard-of-care, patients’ lives are profoundly impacted.

That is why at Domain we are actively working to understand the underlying factors guiding disease progression. We’re exploring the tumor microenvironment in CTCL and the predictive biomarkers available for clinical use.

With the support of ANR, the French National Research Agency as a part of investment plan, we are part of the Hospital-University Research in Health (RHU) SPRINT aiming to revolutionize the management of patients with CTCL and deliver a new cure paradigm as a standard-of-care. This consortium is at the beginning of the collaborative journey with world-class academics and highly innovative companies, including Université Paris Cité HCL - Hospices Civils de Lyon Greater Paris University Hospitals - AP-HP CHU de Bordeaux Inserm TheraPanacea, and more. United in our commitment, we are pushing the boundaries of therapeutic innovation, bringing new hope to CTCL patients.

We’re proud to contribute to this project with our innovative precision research and our novel drug candidate, DT-7012, a Treg depleting anti-CCR8 monoclonal antibody. This best-in-class candidate holds an immense potential to overcome Treg-mediated resistance to , reshape the tumor microenvironment, and unlock the immune system’s cancer fighting abilities.

The Skin Cancer Foundation

23/05/2024

As we mark the 250th year anniversary of the first randomised trial, it is a timely moment to reflect on the significant progress in and its monumental impact on human health.

In the field of cancer treatment, the research journey has seen many successful therapeutic strategies and substantial innovation in and regulatory frameworks. Yet, the quest for a cure continues. This highlights the critical need for trials that are not only patient-centric, but also strategically planned, and executed with precision.

Due to the heterogenous nature of cancer, its mechanisms of resistance remain a big challenge. At Domain, we’re dedicated to understanding these complexities to determine an optimal therapeutic strategy.

We are at the forefront of developing novel treatments that target G Protein Coupled Receptor (GPCR) mediated immunosuppression. GPCRs have long been overlooked in cancer therapy, but their significance is now undeniable to advance innovation the field. They play a pivotal role in shaping immune responses against tumors and their modulation holds an immense promise to redefine cancer treatment.

We apply thoughtful design to our trials, combining strategic GPCR therapeutic targets with comprehensive biomarkers, carefully selected patient sub-populations and robust data management to enhance trial efficiency and success rates aiming to turn non-responder cancer patients into responders.

Our lead clinical candidate, DT-9081, the EP4R antagonist is moving towards Phase II trials and our groundbreaking Treg-depleting anti-CCR8 monoclonal antibody candidate, DT-7012, is expected to start Phase I trials in mid-2025. This progress would not be possible without the amazing dedication of our team, collaborations, innovation, and our shared passion for advancing therapeutic progress in cancer therapy.

On the clinical trials day, and every day, we salute patients, clinicians, investigators and researchers whose unwavering efforts are revolutionising the cancer treatment landscape and paving a way to a healthier future for millions of people across the globe.

Join us in this celebration of progress and hope. Together, let’s make a difference!

Adresse

BioParc – 850 Bld Sébastien Brant
Strasbourg
67400

Téléphone

+ 33 3 90 40 61 52

Site Web

http://www.domaintherapeutics.com/

Notifications

Soyez le premier à savoir et laissez-nous vous envoyer un courriel lorsque Domain Therapeutics publie des nouvelles et des promotions. Votre adresse e-mail ne sera pas utilisée à d'autres fins, et vous pouvez vous désabonner à tout moment.